Striatal dopamine-stimulated adenylate cyclase activity reflects susceptibility of rats to 7,12-dimethylbenz[a]anthracene-induced mammary tumor development.
The relationship between striatal dopamine-stimulated adenylate cyclase (DAC) and 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors was studied. An inverse correlation between activity of this enzyme and the number and growth of tumors was observed in several strains and substrains of rats. Chronic, but not acute, restraint stress inhibited tumor growth and increased DAC activity. No correlation between enzyme activity and the number of tumors was found in the stress study. Increased DAC activity appears to protect or inhibit DMBA mammary tumor development in rats.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000262:Adenylyl Cyclases / Q000032:analysis*; D000818:Animals; D003342:Corpus Striatum / Q000201:enzymology*; D004298:Dopamine / Q000494:pharmacology*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced*; D051381:Rats; D011919:Rats, Inbred Strains; D012149:Restraint, Physical; D013045:Species Specificity
D015127:9,10-Dimethyl-1,2-benzanthracene; D000262:Adenylyl Cyclases; D004298:Dopamine